PRX-102 Slows Kidney Disease Progression in Fabry Patients Previously on Replagal

PRX-102 Slows Kidney Disease Progression in Fabry Patients Previously on Replagal

287551

PRX-102 Slows Kidney Disease Progression in Fabry Patients Previously on Replagal

One year of treatment with PRX-102 (pegunigalsidase alfa), an investigational enzyme replacement therapy (ERT), safely and effectively slowed kidney disease progression in adults with Fabry disease who were previously treated with Replagal (agalsidase alpha), according to final results from the Phase 3 BRIDGE clinical trial. Data also showed that improvements in patients’ kidney function were accompanied by a reduction in the levels of globotriaosylsphingosine (Lyso-Gb3) — a biomarker of Fabry disease — further supporting the…

You must be logged in to read/download the full post.